Skip to main content

Table 2 Clinical characteristics of post-COVID-19 syndrome

From: Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

 

N = 29

Symptoms—n (%)

 

 Fatigue

25 (86%)

 Muscle pain

18 (62%)

 Dyspnea

14 (48%)

 Inappropriate sinus tachycardia

9 (31%)

 Low-grade fever

9 (31%)

Functional status

 

 Grade 0

0 (0%)

 Grade I—n (%)

7 (24%)

 Grade II—n (%)

8 (27.5%)

 Grade III—n (%)

5 (17.2%)

 Grade IV—n (%)

9 (31%)

Median number of days until evaluation days (IQR)

57 (42–71)

Median number of days to extra-respiratory positive RT- PCR (IQR)

55 (39–67)

SARS-CoV-2 IgG tests—n (%)

25 (86%)

Hemoglobin (g/dL)—median (IQR)

14.3 (13.2–15)

Lymphocyte count (× 10E3/µl)—median (IQR)

1.4 (1.2–1.7)

Platelet count (× 10E3/µL)—median (IQR)

202 (184–238)

Serum creatinine (mg/dL)—median (IQR)

0.72 (0.63–0.82)

Alanin aminotransferase (U/L)—median (IQR)

24 (20–39.5)

  > 40 U/L—n (%)

7 (25%)

  ≤ 40 U/L—n (%)

21 (75%)

Ferritin (µg/L)—median (IQR)

100 (38.5–204)

  > 205 (µg/L)—n (%)

7 (25%)

  ≤ 205 (µg/L)—n (%)

21 (75%)

Positive SARS-CoV-2 RT-PCR

 

 Plasma—n (%)

13 (44.8%)

 Stool—n (%)

5 (17.2%)

 Urine—n (%)

4 (13.7%)

 At least one positive result—n (%)

15 (51.7%)

 Two positive results—n (%)

5 (17,2%)

 Three positive results—n (%)

2 (6.8%)

  1. n  number, IQR  interquartile range